SAFETY/EFFICACY OF IV ANTI-D FOR TREATMENT OF THROMBOCYTOPENIA IN HCV

IV 抗 D 治疗 HCV 血小板减少症的安全性/有效性

• 批准号: 7604197
• 负责人: KRISTEN M MARKS
• 金额: $ 0.18万
• 依托单位: WEILL MEDICAL COLL OF CORNELL UNIV
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604197
• 关键词: Blood group antibody D; Computer Retrieval of Information on Scientific Projects Database; Dose; Funding; Grant; HIV Seropositivity; Hepatitis C; Infection; Institution; Intravenous; Patients; Pilot Projects; Platelet Count measurement; Research; Research Personnel; Resources; Safety; Source; Thrombocytopenia; United States National Institutes of Health; base; prospective

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This will be a prospective pilot study of the safety and efficacy of intravenous Anti-D for the treatment of significant thrombocytopenia prior to or during the treatment of hepatitis C infection (with peginterferon-based therapy) in HIV-positive and HIV-negative patients. Hypothesis: Intravenous anti-D will increase platelet counts above the threshold of 50,000/uL recommended for the initiation of peginterferon therapy. Intravenous Anti-D will increase platelet counts above the threshold of 50,000/uL recommended for the dose reduction of peginterferon therapy.

这个子项目是众多研究子项目之一